Personalis (NASDAQ:PSNL) Cut to Sell at Wall Street Zen

Wall Street Zen cut shares of Personalis (NASDAQ:PSNL) from a hold rating to a sell rating in a research report report published on Saturday morning.

Several other equities analysts have also recently commented on the company. Lake Street Capital reiterated a “buy” rating and set a $11.00 target price on shares of Personalis in a research note on Wednesday, November 5th. Needham & Company LLC upped their price target on shares of Personalis from $10.00 to $12.00 and gave the company a “buy” rating in a report on Friday. HC Wainwright increased their price objective on shares of Personalis from $8.50 to $10.00 and gave the company a “buy” rating in a research note on Thursday, November 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Personalis in a report on Thursday, January 22nd. Finally, BTIG Research increased their target price on Personalis from $12.00 to $13.00 and gave the stock a “buy” rating in a report on Wednesday, February 11th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Personalis has an average rating of “Moderate Buy” and a consensus price target of $11.14.

Personalis Stock Performance

Personalis stock opened at $9.06 on Friday. Personalis has a 1 year low of $2.83 and a 1 year high of $11.50. The firm has a 50 day moving average price of $8.83 and a 200 day moving average price of $8.04. The company has a market cap of $947.95 million, a price-to-earnings ratio of -9.96 and a beta of 2.02.

Personalis (NASDAQ:PSNL) last released its quarterly earnings data on Thursday, February 26th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.05. The company had revenue of $17.35 million during the quarter, compared to the consensus estimate of $17.12 million. Personalis had a negative net margin of 116.69% and a negative return on equity of 42.81%. Sell-side analysts predict that Personalis will post -1.4 EPS for the current year.

Institutional Trading of Personalis

Several hedge funds have recently bought and sold shares of the company. T. Rowe Price Investment Management Inc. boosted its stake in shares of Personalis by 273.9% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 10,780,290 shares of the company’s stock worth $85,812,000 after acquiring an additional 7,896,714 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in shares of Personalis by 1,332.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,448,585 shares of the company’s stock worth $11,531,000 after buying an additional 1,347,439 shares during the period. Kennedy Capital Management LLC boosted its holdings in shares of Personalis by 196.2% in the third quarter. Kennedy Capital Management LLC now owns 1,935,078 shares of the company’s stock worth $12,617,000 after buying an additional 1,281,695 shares during the period. Aberdeen Group plc increased its position in shares of Personalis by 36.1% in the fourth quarter. Aberdeen Group plc now owns 3,249,895 shares of the company’s stock worth $25,869,000 after acquiring an additional 861,948 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of Personalis by 165.6% during the second quarter. Geode Capital Management LLC now owns 1,365,598 shares of the company’s stock valued at $8,960,000 after acquiring an additional 851,422 shares during the period. 61.91% of the stock is currently owned by institutional investors.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.